The psychedelic sector never sits still. Here is what happened during the week of November 3–9, 2025, and why each story matters for the companies and investors we track.
Compass Pathways plc (CMPS): Compass accelerates commercial launch plans by 9-12 months in Q3 update
In its third-quarter 2025 results, Compass Pathways said a positive Type B meeting with the FDA supports a rolling NDA submission for COMP360 psilocybin in treatment-resistant depression and that it now expects a potential approval decision in late 2026 or early 2027, roughly 9 to 12 months earlier than previously guided. The company detailed plans to accelerate commercial launch preparations. Shares reacted sharply to the improved regulatory timeline.
Source: businesswire.com
atai Life Sciences / Beckley Psytech (ATAI): atai and Beckley Psytech complete combination to form AtaiBeckley
atai Life Sciences and Beckley Psytech completed their strategic combination to create AtaiBeckley, following shareholder approval at a November 4 extraordinary general meeting where roughly 98% of votes cast favored the deal. Shareholders also approved redomiciliation to Delaware. The merger consolidates BPL-003 (mebufotenin) and atai's broader pipeline under one company positioned as a leading psychedelic mental-health developer.
Source: globenewswire.com
GH Research PLC (GHRS): GH Research reports Q3 2025 results with $293.9 million cash and durable 5-MeO-DMT data
GH Research reported third-quarter 2025 results, ending the period with $293.9 million in cash and marketable securities. The company highlighted its Phase 2b program for inhalable 5-MeO-DMT (GH001) in treatment-resistant depression, including an open-label extension showing a 73% remission rate at six months, and reaffirmed plans to start a global pivotal program in 2026. It also continued working with the FDA to resolve the remaining topic on its U.S. IND clinical hold.
Source: globenewswire.com
Mind Medicine (MindMed) Inc. (MNMD): MindMed reports Q3 2025 results with MM120 Phase 3 program on track
MindMed reported third-quarter 2025 results, with R&D expense of about $31.0 million driven by its MM120 (LSD) program. Management said enrollment across its three pivotal MM120 orally disintegrating tablet trials for anxiety and depression remained on track, with Voyage topline data expected in the first half of 2026 and additional Phase 3 readouts later in 2026. CEO Rob Barrow characterized 2025 as a year of strong execution.
Source: businesswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.